lipitor discontinue
Click on image below to visit
The size of the market for atorvastatin has prompted the generic drug manufacturing company Ranbaxy to challenge the validity of some of Pfizer’s patents in patent courts across the world. As of March 2007, courts had mostly upheld the validity of Pfizer’s original patent for atorvastatin, which is due to expire in European territories in 2011 (but 2007 in Canada). However a later patent for the specific enantiomer of the atorvastatin formula that is medically useful, which would have given Pfizer longer protection, has fared less well. Although upheld in the United States[6], Spain, and Ecuador, the enantiomer patent has been declared invalid by courts in Austria, Australia, Canada, the Netherlands and the United Kingdom[7].
WASHINGTON — Greater LDL Cholesterol Reduction with VYTORIN Compared to Resulted in Greater LDL Cholesterol Goal Attainment
Results from a new clinical study conducted in 1,229 patients with type 2 diabetes mellitus and high cholesterol showed that VYTORIN(R) (ezetimibe/simvastatin) provided superior reduction in LDL "bad" cholesterol compared to (R) (atorvastatin) in comparisons of the recommended usual starting doses, according to data presented today at the American Diabetes Association’s (ADA) 66th Annual Sc